14 results about "Infectious peritonitis" patented technology

This invention provides a saRNA vaccine for the prevention of feline infectious peritonitis (FIP). The saRNA vaccine is a composition comprising saRNA A and saRNA B. The assembly elements of the saRNA include: a 5′ UTR, replicases nsp1-nsp4, a subgenomic promoter, a Kozak sequence, nucleic acid sequence A or nucleic acid sequence B, a 3′ UTR, and a polyadenylated tail (polyA). The saRNA vaccine provided by this invention is effective for the immunization prophylaxis of FIP types I and II. Furthermore, based on the development of this vaccine, by replacing the coding sequences of different antigens, it can be extended to the development of vaccines for other coronaviruses or other veterinary pathogens, demonstrating significant technological transfer value and industrialization prospects.

The invention discloses application of ailanone in preparation of a medicine for treating feline infectious peritonitis, and belongs to the field of biological medicine. The change of the expression quantity of the feline infectious peritonitis virus N protein is detected through indirect immunofluorescence and western blot, and the change of the quantity titer of the feline infectious peritonitis virus is detected through TCID50. Results show that ailanone has an obvious effect of resisting the feline infectious peritonitis virus, the inhibitory effect on the feline infectious peritonitis virus is enhanced along with increase of the drug concentration, and the half effective concentration is 0.09 mu M. Meanwhile, drug inhibition tests show that ailanone has no inhibition effect on feline calicivirus. The invention provides a novel therapeutic drug and strategy for treating feline infectious peritonitis.

This invention provides a broad-spectrum mRNA vaccine for the prevention of feline infectious peritonitis (FIP) and its preparation method. The vaccine comprises mRNA molecule 1 and mRNA molecule 2. mRNA molecule 1 contains an LS-FIPV-I MEV-N-M antigen protein coding sequence composed of a self-assembled LS nanoparticle fusion sequence based on a tandem neutralizing epitope of the FIPV type I S protein and a T-cell epitope, as well as antigen-coding sequences of the N and M proteins. mRNA molecule 2 contains an antigen protein coding sequence of an LS nanoparticle structure self-assembled from the FIPV type II S protein receptor domain RBD. This invention, through the combination of two mRNA molecules, can achieve broad-spectrum protection against both FIPV types I and II while mitigating the risk of adverse drug reaction (ADE).

The invention relates to the technical field of veterinary drugs, and particularly provides a polynucleotide molecule composition for preventing cat infectious peritonitis, a chimeric polynucleotide molecule and an mRNA vaccine. In order to overcome the ADE effect caused by S protein full-length antigen in the prior art, FIPV N protein without ADE risk is adopted and is combined with screened S protein specific T cell and B cell epitopes. Core schemes include two classes: one is a separate polynucleotide composition comprising epitope peptides encoding N and S proteins; and 2, a single chimeric polynucleotide encoding N protein and S protein epitope peptides. The polynucleotides are optimized by codons and encapsulated in lipid nanoparticles (LNP) to prepare vaccines. Experiments prove that the vaccine can synergistically stimulate powerful immune response, the survival rate of immune cats is remarkably increased to 80%-100% from standard 40% on the premise that ADE is not caused, and FIP is effectively prevented.

The invention discloses a recombinant feline infectious peritonitis double-layer vesicle tracer virus as well as a construction method and application thereof, and belongs to the technical field of bioengineering. A CRISPR / Cas9 mediated homologous recombination technology is used, on the basis of a reverse genetic manipulation platform, an Nsp3 region of plasmid pBAC-FIBV-791146 is replaced with a reporter gene sequence, then the feline infectious peritonitis virus is rescued, and the recombinant feline infectious peritonitis bilayer vesicle tracer virus is formed. The biological characteristics of the strain and the tracing effect of the double-membrane vesicles are measured, it is proved that insertion of the ZsGreen gene does not affect virus proliferation, but the recombinant virus has the characteristic of tracing the double-membrane vesicles, and the recombinant virus can serve as a research tool for monitoring the forming mechanism of the double-membrane vesicles and a drug screening tool for resisting the feline infectious peritonitis virus.

The application relates to a cat infectious peritonitis virus S protein receptor binding region monoclonal antibody and application thereof, relates to the technical field of biology, and aims to provide a cat infectious peritonitis virus S protein receptor binding region monoclonal antibody and application thereof.The amino acid sequence of a heavy chain variable region of the monoclonal antibody is shown in a sequence table SEQ ID NO.1, and the amino acid sequence of a light chain variable region is shown in a sequence table SEQ ID NO.2.The application adopts Western blot and IFA methods to identify the reactivity of MAb, and identifies an antigen epitope recognized by MAb.The antigen epitope is conservative in type I cat coronavirus, which indicates that the monoclonal antibody can recognize various type I FCoV strains, has broad spectrum, and is not accidentally directed to a single strain.The antigen epitope has no cross reaction with type II, which indicates that the specificity is high, can be used for distinguishing type I and type II infections, and has diagnostic application value.

The invention provides a broad-spectrum mRNA vaccine for preventing feline infectious peritonitis and a preparation method thereof, the vaccine comprises an mRNA molecule 1 and an mRNA molecule 2, the mRNA molecule 1 comprises a self-assembled LS nanoparticle fusion sequence based on a neutralizing epitope of series FIPV type I S protein and a T cell epitope, and the mRNA molecule 2 comprises a self-assembled LS nanoparticle fusion sequence based on series FIPV type I S protein. The LS-FIBV-I MEV-N-M antigen protein coding sequence is composed of the antigen coding sequences of the N protein and the M protein; the mRNA molecule 2 comprises an antigen protein coding sequence which is fused and self-assembled by an FIPV II type S protein receptor structural domain RBD and has an LS nano-particle structure. According to the invention, through the combination of double mRNA molecules, while the ADE risk is avoided, the broad-spectrum protection of the FIPV type I and the FIPV type II is realized.

This invention belongs to the field of biomedicine, specifically relating to a secretory self-assembling nanoparticle mRNA vaccine for feline infectious peritonitis and its application. First, this invention constructs a Ferritin fusion antigen by fusing the RBD or S1 fragment of the FIPV S protein with ferritin. Second, this invention constructs an mRNA encoding the aforementioned Ferritin fusion antigen. The mRNA is delivered into host cells via lipid nanoparticles (LNPs), where it is translated and expressed in the cytoplasm. The Ferritin fusion antigen then forms a nanoparticle structure within the cell using its natural self-assembly properties, eliminating the need for in vitro assembly steps. Compared to traditional nanoparticle vaccines, this method avoids steps such as in vitro induction expression, purification, and adjuvant addition, simplifying the production process, improving immunogenicity, reducing the risk of adverse drug reactions (ADE), and enhancing safety. Furthermore, it significantly improves humoral and cellular immunity.

The present application relates to the technical field of virus detection, in particular to a primer probe combination for feline infectious peritonitis virus serotyping, application and kit thereof. The primer probe combination comprises FIPV N gene specific primer probe, FIPV I serotype S gene specific primer probe and FIPV II serotype S gene specific primer probe. The three groups of primer probes can be used for serotyping identification of FIPV I serotype strain and FIPV II serotype strain. The primer probe combination can be used for differential diagnosis of different serotypes of FIPV by fluorescence quantitative PCR method, and has the advantages of accurate identification, high sensitivity, simple operation, short time consumption and the like, and can provide effective technical means for rapid diagnosis of feline infectious peritonitis virus in China and prevention of feline infectious peritonitis.

The invention provides a self-assembled ferritin nanoparticle recombinant protein and application thereof in preparation of cat infectious peritonitis virus vaccines, and belongs to the technical field of nano vaccines. The self-assembly ferritin nanoparticle recombinant protein is formed by self-assembly of ST-N-Fel protein, HCV E2-SC protein and IFN gamma-SC protein. According to the invention, the N protein of FIPV is displayed on the surface of the self-assembled ferritin nanoparticle, an immunopotentiator capable of enhancing cellular immunity and a targeting factor are added to optimize the recombinant protein of the self-assembled ferritin nanoparticle, and IFN gamma-SC and HCV E2-SC can be efficiently coupled with ST-N-Fel through covalent linkage between SpyTag and SpyCatcher. The self-assembled ferritin nanoparticle recombinant protein provided by the invention can be used for preparing an FIPV vaccine, and the vaccine has the capability of reducing ADE risk while inducing protective immune response.